Blog
RSS FeedPosted by Michael Wonder on 30 Oct 2023
Expanded access to chronic heart failure treatment on the PBS
30 October 2023 - More Australians with chronic heart failure will have access to subsidised treatment under the PBS. ...
Posted by Michael Wonder on 29 Oct 2023
100,000 patients eligible for heart drug under PBS
28 October 2023 - Almost 100,000 patients are set to save hundreds of dollars per year as access to a ...
Posted by Michael Wonder on 16 Oct 2023
Cheaper medicines for cervical cancer, urotherial cancer and spinal muscular atrophy
16 October 2023 - From 1 October 2023, Australians with cervical cancer, urothelial cancer and spinal muscular atrophy will have access ...
Posted by Michael Wonder on 30 Sep 2023
New Zealand Pharmaceutical Schedule - 1 October 2023
1 October 2023 - The October 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Sep 2023
Schedule of Pharmaceutical Benefits - 1 October 2023
1 October 2023 - The October 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 06 Sep 2023
'Joint reimbursement of Opdivo, CDx platform marks milestone in gastric cancer but challenges remain'
6 September 2023 - Oncology experts celebrated the joint reimbursement of Opdivo together with its PD-L1 IHC 28-8 PharmDx companion ...
Posted by Michael Wonder on 31 Aug 2023
New Zealand Pharmaceutical Schedule - 1 September 2023
1 September 2023 - The September 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Aug 2023
Schedule of Pharmaceutical Benefits - 1 September 2023
1 September 2023 - The September 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 15 Aug 2023
New treatments for people with chronic migraine and soft tissue sarcoma added to the PBS
14 August 2023 - From August 2023, Australians with chronic migraine and soft tissue sarcoma will have access to new ...
Posted by Michael Wonder on 03 Jul 2023
Novartis’ Scemblix gets benefit to treat chronic myeloid leukaemia third or more times
30 June 2023 - Novartis' Scemblix (asciminib) will receive reimbursement for the third-line or more treatment of chronic myeloid leukaemia ...
Posted by Michael Wonder on 02 Jul 2023
Widened eligibility for oral antiviral Paxlovid, plus new medicines on PBS
2 July 2023 - From 1 July 2023, Australians with severe thrombocytopenia and diabetic kidney disease will have access to ...
Posted by Michael Wonder on 01 Jul 2023
Schedule of Pharmaceutical Benefits - 1 July 2023
1 July 2023 - The July 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 01 Jul 2023
Changes to the National Immunisation Program effective 1 July 2023
30 June 2023 - From 1 July 2023, Vaxelis will be added to the National Immunisation Program as an alternative ...
Posted by Michael Wonder on 01 Jul 2023
New Zealand Pharmaceutical Schedule - 1 July 2023
1 July 2023 - The July 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 07 Jun 2023
PHARMAC confirms funding of rituximab for IgG4 related disease
7 June 2023 - PHARMAC has published a notification for widened access to rituximab (Riximyo) for people with the chronic inflammatory ...